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Studies in animal models suggest that complement
activation is crucial in the pathogenesis of anti-neutrophil
cytoplasmic antibody–associated vasculitis (AAV). Here we
investigate the circulating complement activation profile of
66 patients with active stage AAV compared to that of 54
patients with AAV in remission. Plasma levels of C3a, C5a,
soluble C5b-9, and Bb, all determined by enzyme-linked
immunosorbent assay, were significantly higher in active
stage than in remission of AAV, while plasma levels of
properdin were significantly lower in the former than the
latter disease stage. There was no significant difference in the
plasma levels of C4d between active stage and remission. The
plasma level of Bb in patients with active AAV significantly
correlated with the proportion of total and cellular crescents
in the renal biopsy, the erythrocyte sedimentation rate, and
the Birmingham Vasculitis Activity Scores. Thus, systemic
activation of complement by the alternative pathway takes
place in human AAV. Circulating Bb might be a useful
biomarker in assessing disease activity of AAV.
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Anti-neutrophil cytoplasmic antibody (ANCA)–associated
vasculitis (AAV) is characterized by pauci-immune necrotiz-
ing inflammation of the small blood vessels. AAV comprises
granulomatosis with polyangiitis (GPA, previously named
Wegener’s granulomatosis), microscopic polyangiitis, and
Churg–Strauss syndrome. ANCAs are predominantly IgG
autoantibodies directed against neutrophil cytoplasmic con-
stituents, in particular proteinase 3 and myeloperoxidase
(MPO),1,2 and are useful serological markers of AAV.
The complement system has a central role in innate and
humoral immunity, and is composed of more than 30
plasma- and membrane-bound proteins. Activation of the
complement system mainly follows three different pathways:
the classical, the lectin, or the alternative pathway, distin-
guished by the factors that trigger complement activation. It
was previously assumed that the complement system is not
involved in the pathogenesis of AAV, as there is little
immunoglobulin or complement deposition at lesional sites
and AAV is generally not associated with hypocomplemente-
mia. Recent studies in the mouse model of anti-MPO
IgG-mediated glomerulonephritis suggest that complement
activation, via the alternative pathway, is crucial for the
disease development.3–5 Our previous study in human AAV
indicated that patients with renal C3c deposition had a
higher level of proteinuria and a poorer initial renal
function.6 In a subsequent study, we confirmed complement
activation via the alternative pathway in kidneys of patients
with AAV.7 However, direct evidence for systemic comple-
ment activation in human AAV is lacking. To address this
issue, we measured plasma levels of various complement
components in patients with AAV in both active and
quiescent phases of the diseases, and correlated circulating
levels of various complement components with clinical and
pathological parameters.
RESULTS
Demographic and general data
Of the 66 patients with AAV in active stage, 29 were male and
37 were female, with an age of 55.4±15.7 (range 14–82) years
at diagnosis. The median interval from complaints to
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diagnosis was 3 (range 0.3–60.8) months. At the time of
diagnosis, 7 of the 66 patients had complaints less than 1
month; and 32 of the 66 patients had complaints more than 3
months. The level of initial serum creatinine was 371.3±258.3
(range 57–1168) mmol/l. The level of urinary protein excretion
was 2.49±1.67 (range 0–7.35) g per 24 h. The level of
Birmingham Vasculitis Activity Scores (BVAS)8 was 20.3±5.2
(range 11–30). In the renal specimen of these patients, little
or no staining for IgG, IgA, or IgM (p1þ on a scale of 0 to
4þ ) was observed by immunofluorescence microscopy. No
electron dense deposits were detected by electron microscopy.
The clinical and histopathological data were listed in Table 1.
In addition, among the 46 patients with active lupus
nephritis, the level of systemic lupus erythematosus disease
activity index was 21.5±5.7 (range 9–36).
Of the 54 patients in remission stage of AAV, 21 were male
and 33 were female, with an age of 59.3±15.2 (range 18–81)
years at diagnosis. The level of serum creatinine at sampling
was 193.0±147.9 (range 58–642) mmol/l. The BVAS levels of
all the 54 patients in remission stage of AAV were zero.
Plasma levels of soluble C5b-9 (Sc5b-9), C5a, and C3a
The level of plasma Sc5b-9 was significantly higher in patients
with AAV with active disease compared with patients in
remission and normal controls (955.81±321.39 vs. 345.99±
106.84 ng/ml, Po0.01; 955.81±321.39 vs. 360.82±164.51 ng/ml,
Po0.01), but significantly lower than that in patients with
lupus nephritis (955.81±321.39 vs. 1477.68±733.80 ng/ml,
Po0.01). There was no significant difference in plasma
concentration of Sc5b-9 between patients with AAV in
remission and normal controls (345.99±106.84 vs. 360.82±
164.51 ng/ml, P40.05) (Figure 1a).
Plasma C5a levels were significantly higher in patients
with active AAV compared with patients in remission,
patients with lupus nephritis, and normal controls (51.65±
34.75 vs. 9.78±5.81 ng/ml, Po0.01; 51.65±34.75 vs.
23.29±18.37 ng/ml, Po0.01; 51.65±34.75 vs. 8.19±
5.44 ng/ml, Po0.01, respectively). There was no significant
difference in plasma levels of C5a between patients with AAV
in remission and normal controls (9.78±5.81 vs. 8.19±
5.44 ng/ml, P40.05) (Figure 1b).
The plasma level of C3a in patients with active AAV was
significantly higher compared with patients in remission,
patients with lupus nephritis, and normal controls (2178.67±
668.91 vs. 268.50±211.53 ng/ml, Po0.01; 2178.67±668.91 vs.
1164.83±1063.07 ng/ml, Po0.01; 2178.67±668.91 vs. 100.87±
70.55 ng/ml, Po0.01, respectively). However, the level of plasma
C3a in patients with AAV in remission was still significantly
higher compared with normal controls (268.50±211.53 vs.
100.87±70.55 ng/ml, Po0.01) (Figure 1c).
The plasma levels of Bb and properdin
As data from animal models suggest that complement
activation via the alternative pathway has a crucial role in
the development of AAV,3 we further investigated plasma
levels of two important factors in the alternative pathway,
properdin and Bb. Measurement of properdin and Bb in
plasma provides evidence for the involvement of the
alternative complement pathway.9–11
The plasma levels of Bb were significantly higher in patients
with AAV in active stage compared with patients in remission
and normal controls (1.30±0.68 vs. 0.62±0.34mg/ml,
Po0.01; 1.30±0.68 vs. 0.63±0.26mg/ml, Po0.01, respec-
tively). No significant difference was found in plasma level of
Bb between AAV patients in remission and normal controls
(0.62±0.34 vs. 0.63±0.26mg/ml, P40.05). The plasma levels
of properdin were significantly lower in AAV patients with
active disease compared with patients in remission and normal
controls (10.35±5.64 vs. 35.96±13.87mg/ml, Po0.01; 10.35±
5.64 vs. 22.57±9.67mg/ml, Po0.01, respectively). The plasma
levels of properdin in AAV patients in remission were
significantly higher than that in normal controls (35.96±
13.87 vs. 22.57±9.67mg/ml, Po0.01). However, there were no
significant differences in Bb and properdin levels between
patients with active AAV and patients with lupus nephritis
(1.30±0.68 vs. 1.47±0.87mg/ml, P40.05; 10.35±5.64 vs.
11.61±6.92mg/ml, P40.05, respectively) (Figure 1d and e).
Table 1 | Clinical and histopathological data of patients with
active AAV
Values
Total number of patients 66
Male/female 29/37
Average age at onset of the disease (years) 55.36±15.72
Scr (mmol/l)
Mean±s.d. 371.3±258.3
Range 57–1168
eGFR (ml/min per 1.73m2)
Mean±s.d. 24.43±23.54
Range 0.7–123.9
ESR (mm per 1 h) 73.27±41.35
ANCA level (RU/ml) 115.97±52.48
Renal insufficiency at diagnosis 60 (89.5%)
Urinary protein (g per 24 h)
Mean±s.d. 2.49±1.67
Range 0–7.35
Skin rash 10 (14.9%)
Arthralgia 25 (37.3%)
Muscle pain 32 (47.8%)
Pulmonary 32 (47.8%)
ENT 29 (43.3%)
Ophthalmic involvement 13 (19.4%)
Gastrointestinal involvement 12 (17.9%)
Nervous system 3 (4.5%)
BVAS 20.27±5.18
Average glomeruli per biopsy 25.62±13.09
Glomerular lesions (%)
Total crescents 59.39±29.00
Cellular crescents 15.91±20.70
Abbreviations: AAV, anti-neutrophil cytoplasmic antibody–associated vasculitis;
ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity
Scores; eGFR, estimated glomerular filtration rate; ENT, ear, nose, and throat; ESR,
erythrocyte sedimentation rate; s.d., standard deviation.
Data were collected at presentation.
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Plasma levels of C4d
The complement fragment C4d is a product derived from
activation of C4, which is needed in both the classic pathway
and the lectin pathway.
The plasma levels of C4d were significantly higher in
patients with AAV with active disease compared with patients
with lupus nephritis and normal controls (13.43±6.56 vs.
4.59±4.97 mg/ml, Po0.01; 13.43±6.56 vs. 1.36±0.82 mg/ml,
Po0.01, respectively). The plasma level of C4d in
AAV patients in remission was significantly higher than that
in normal controls (11.24±8.49 vs. 1.36±0.82 mg/ml,
Po0.01). However, there was no significant difference in
the plasma levels of C4d between AAV patients with active
disease and AAV patients in remission (Figure 1f).
Plasma levels of complement components in sequential
samples from AAV patients
To further confirm the changes of circulating complement
levels between active and quiescent disease, sequential plasma
samples of both active stage and remission stage, from 20
patients with AAV, were measured. The plasma levels of Sc5b-
9, C5a, C3a, and Bb were significantly higher in active stage
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Figure 1 |Plasma levels of complement components in patients with active anti-neutrophil cytoplasmic antibody–associated
vasculitis (AAV), active lupus nephritis (LN), remission of AAV, and in normal controls. Horizontal solid lines indicated the mean level.
(a) Plasma levels of Sc5b-9. (b) Plasma levels of C5a. (c) Plasma levels of C3a. (d) Plasma levels of Bb. (e) Plasma levels of properdin. (f) Plasma
levels of C4d.
Kidney International (2012) 83, 129–137 131
S-J Gou et al.: Complement activation of human AAV c l in i ca l inves t iga t ion
than that in remission (964.98±319.51 vs. 343.25±
113.98 ng/ml, Po0.001; 31.63±27.14 vs. 9.64±4.75 ng/ml,
P¼ 0.002; 1863.54±832.90 vs. 340.66±274.46 ng/ml,
Po0.001; 1.17±0.80 vs. 0.65±0.36mg/ml, P¼ 0.001, respec-
tively). For every patient, plasma levels of Sc5b-9 and C3a in
remission were much lower than those in active stage.
Eighteen of these 20 patients had a decrease in plasma level
of C5a in remission compared with that in active stage,
whereas only two patients had a very slight increase in plasma
level of C5a in remission compared with that in active stage.
Similarly, 18 of these 20 patients had a decrease in plasma
level of Bb in remission compared with that in active stage,
whereas two patients had a very slight increase in plasma level
of Bb in remission compared with that in active stage.
The plasma level of properdin was significantly lower in
active stage than that in remission (11.17±5.39 vs. 34.13±
10.60mg/ml, Po0.001). For every patient, the plasma level of
properdin in remission stage was much higher than that in
active stage. However, no significant difference was found in
plasma level of C4d between the active and the remission stage
(10.73±6.25 vs. 11.47±8.32mg/ml, P¼ 0.765) (Figure 2).
Plasma levels of intact complement components C4, C2, and
factor B
The plasma levels of C4, C2, and factor B were signifi-
cantly higher in patients with AAV in active stage than those
in normal controls (0.22±0.08 vs. 0.18±0.03 mg/ml,
P¼ 0.01; 60.69±18.51 vs. 47.63±8.75 mg/ml, Po0.01;
418.18±160.40 vs. 295.99±91.94 mg/ml, Po0.01, respec-
tively). The plasma levels of C4, C2, and factor B were signifi-
cantly lower in patients with lupus nephritis than those in
normal controls (0.10±0.07 vs. 0.18±0.03 mg/ml, Po0.01;
29.00±21.25 vs. 47.63±8.75 mg/ml, Po0.01; 213.83±
239.33 vs. 295.99±91.94 mg/ml, Po0.01, respectively). The
plasma levels of C4, C2, and factor B were still significantly
higher in patients with AAV in remission than those in
normal controls (0.20±0.04 vs. 0.18±0.03 mg/ml, P¼ 0.02;
55.32±17.21 vs. 47.63±8.75 mg/ml, P¼ 0.01; 399.11±94.46
vs. 295.99±91.94 mg/ml, Po0.01, respectively). However,
there were no significant differences in plasma levels of C4,
C2, and factor B between patients with AAV in active stage
and those in remission (0.22±0.08 vs. 0.20±0.04 mg/ml,
P40.05; 60.69±18.51 vs. 55.32±17.21 mg/ml, P40.05;
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Figure 2 |Changes of circulating complement levels in 20 anti-neutrophil cytoplasmic antibody–associated vasculitis (AAV)
patients with sequential plasma samples. (a) Plasma levels of Sc5b-9. (b) Plasma levels of C5a. (c) Plasma levels of C3a. (d) Plasma levels
of Bb. (e) Plasma levels of properdin. (f) Plasma levels of C4d.
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418.18±160.40 vs. 399.11±94.46 mg/ml, P40.05, respec-
tively) (Figure 3).
Association between circulating levels of various
complement components and clinicopathological parameters
of patients with active AAV
Of the 66 patients with AAV in active stage, correlation
analysis showed that plasma levels of C5a correlated with that
of Sc5b-9 and C3a (r¼ 0.382, Po0.01; r¼ 0.424, Po0.01;
respectively). Plasma properdin levels inversely correlated
with the proportion of crescents in the renal specimen
(r¼0.292, Po0.05). Plasma Bb levels correlated with
plasma levels of C5a, C3a, and Sc5b-9 (r¼ 0.285, Po0.05;
r¼ 0.257, Po0.05; r¼ 0.384, Po0.01, respectively). Plasma
Bb levels also correlated with BVAS, the level of erythrocyte
sedimentation rate, the proportion of total crescents, and
the proportion of cellular crescents (r¼ 0.286, Po0.05;
r¼ 0.311, Po0.05; r¼ 0.266, Po0.05; r¼ 0.358, Po0.01,
respectively) (Figure 4). In addition, plasma Bb levels
marginally inversely correlated with the proportion of
normal glomeruli (r¼0.241, P¼ 0.05).
Immunohistochemistry for Bb, C3d, and C5b-9
In renal specimens of patients with AAV, immunohistochem-
ical examination revealed that Bb, C3d, and C5b-9 could be
detected along the glomerular capillary wall and mesangial
area of glomeruli of patients with AAV in a granular
pattern (Figure 5). In addition, they could also be detected
in some small arteries, which is consistent with our previous
observations.7
The number of glomeruli analyzed for Bb, C3d, and C5b-9
per biopsy of patients with AAV was 14.34±8.26 (range
4–35), 15.48±9.13 (range 4–34), and 12.07±7.06 (range
4–27), respectively. The mean optical density of Bb, C3d, and
C5b-9 in glomeruli was 0.34±0.23, 0.62±0.30, and
0.05(0.02–0.13), respectively. Correlation analysis showed
that the mean optical density of Bb in renal specimens
correlated with the mean optical density of C3d and C5b-9
(r¼ 0.733, Po0.001; r¼ 0.611, Po0.001, respectively). The
mean optical density of C3d correlated with that of C5b-9
(r¼ 0.436, P¼ 0.018). The mean optical density of C5b-9 in
renal specimens inversely correlated with plasma level of C5a
and Sc5b-9 (r¼0.390, P¼ 0.037 and r¼0.448, P¼ 0.015,
respectively). No correlation was found between the mean
optical density of Bb in renal specimens and the plasma level
of Bb, and no correlation was found between the mean
optical density of C3d in renal specimens and the plasma
level of C3a.
DISCUSSION
Recently, increasing evidence of complement activation in the
pathogenesis of AAV was provided by studies in animal
models.3–5 Our previous study suggested that, in human renal
histopathology, complement activation via the alternative
pathway participated in the development of ANCA-asso-
ciated glomerulonephritis.7 However, the evidence for
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Figure 3 |Plasma levels of C4, C2, and factor B in patients with
active anti-neutrophil cytoplasmic antibody–associated
vasculitis (AAV), active lupus nephritis (LN), remission of AAV,
and in normal controls. Horizontal solid lines indicated the mean
level. (a) Plasma levels of C4. (b) Plasma levels of C2. (c) Plasma
levels of factor B.
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circulating activation of complement system in AAV, a
systemic autoimmune disease, was lacking. Therefore, in
the current study, we measured various circulating comple-
ment components to investigate systemic complement
activation profile of patients with AAV.
Activation of the complement system leads the cleavage of
C3 to C3a and C3b. The three pathways converge at the
formation of C5 convertases capable of cleaving C5 to C5a
and C5b, and then membrane attack complex C5b-9 is
generated by the assembly of C5b through C9. In the current
study, the significant difference in plasma levels of C5a and
Sc5b-9 between AAV patients in active stage and in remission
as well as healthy controls indicates that complement
activation occurs in the development of AAV. Interestingly,
the plasma level of Sc5b-9 in patients with active AAV was
significantly lower than that in patients with active SLE,
whereas the plasma levels of C3a and C5a in patients with
active AAV were significantly higher than that in patients
with active SLE. CD59 is an important complement
membrane inhibitor, which could prevent the formation of
the membrane attack complex by blocking the interaction of
the C5b-8 complex with C9. It was found that the
proportions of several kinds of circulating blood cells with
CD59 expression were significantly reduced in SLE patients.12
Decreased CD59 level might contribute to a significant
increase in plasma Sc5b-9 level in SLE patients. However,
the CD59 expression in patients with AAV needs further
investigation.
In this study, the plasma level of fragment Bb, which
indicates activation of the alternative pathway,9–11 was
significantly higher in AAV patients of active stage than that
in remission and normal controls. It was also found in the
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Figure 4 |Association between circulating levels of Bb and clinicopathological parameters of patients with active anti-neutrophil
cytoplasmic antibody–associated vasculitis (AAV). (a) Association between plasma levels of Bb and Birmingham Vasculitis Activity Scores
(BVAS). (b) Association between plasma levels of Bb and erythrocyte sedimentation rate. (c) Association between plasma levels of Bb and
the proportion of total crescents in renal specimens. (d) Association between plasma levels of Bb and the proportion of cellular crescents.
Bba b cC3d C5b-9
Figure 5 | Immunohistochemistry staining for complement components Bb, C3d, and C5b-9 in renal specimens of patients with
anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis. (a) Immunohistochemical staining of Bb in glomerulus of ANCA-
associated vasculitis. (b) Immunohistochemical staining of C3d in glomerulus of ANCA-associated vasculitis. (c) Immunohistochemical
staining of C5b-9 in glomerulus of ANCA-associated vasculitis.
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current study that plasma Bb concentration correlated with
plasma levels of C3a, C5a, and Sc5b-9, which reflect the
systemic activation of the complement system. These
suggested the complement activation via the alternative
complement pathway occurs in the development of AAV.
More importantly, plasma Bb concentration correlated with
erythrocyte sedimentation rate, BVAS, and the proportion of
crescents in renal histopathology of patients with AAV, which
indicated that circulating Bb level could reflect both systemic
and renal disease activity. In the anti-MPO-induced AAV
mouse model,13 mice deficient for factor B, which is unique
in activation of the alternative pathway, were completely
protected from disease induction,3 indicating that activation
of factor B is indispensable in the pathogenesis of AAV. The
close association between circulating Bb level and disease
activity suggests it to be a potentially useful biomarker for
evaluating disease activity in AAV. In the present study, we
also found that the plasma level of Bb in patients with lupus
nephritis was significantly higher than that in normal
controls, which has been consistent with previous stu-
dies.9,14,15 There is increasing evidence from animal and
human studies that the alternative pathway is involved in the
pathogenesis of lupus nephritis,16,17 which is consistent with
the results presented here. Compared with lupus nephritis,
similar plasma levels of Bb were observed in patients with
AAV, providing additional evidence for activation of the
alternative pathway in AAV.
The current study found that the plasma level of
properdin in patients with AAV in active stage was signifi-
cantly lower than that in normal controls. The level of pro-
perdin inversely correlated with the proportion of crescents
in renal specimens of AAV. These observations provide
additional evidence that activation of the alternative
complement pathway occurs in the development of AAV.
The plasma level of C4d in patients with AAV in active
stage was significantly higher than that in normal controls,
but there was no significant difference in plasma levels of C4d
between patients in active stage and in remission. This
indicated that the classic and/or lectin pathway were also
activated in patients with active AAV, but they were probably
not pathogenic. The complement components, especially
those in classic and lectin pathways, have functions for
clearing apoptotic and necrotic cells. Ogden et al.18 demon-
strated that both MBL and C1q, the first components of the
lectin pathway and classical pathway, could bind to apoptotic
cells and facilitate their clearance by phagocytes, such as
macrophage. Gullstrand et al.19 demonstrated that classical
pathway components C1q, C4, C2, and C3 are involved in
phagocytosis of apoptotic cells by phagocytes. In the present
study, we cannot rule out the possibility that the activation
of lectin pathway and/or classical pathway of the complement
system was involved in clearing apoptotic or necrotic cells in
the chronic inflammation process of AAV. In addition, the
increase of C4d in patients with lupus nephritis in the present
study was consistent with previous reports.15 Interestingly,
the plasma level of C4d in patients with active AAV was much
higher than that of patients with lupus nephritis. This might
be attributed to a somewhat more fulminant disease process
of ANCA-associated glomerulonephritis than lupus nephritis,
e.g., rapid loss of renal function and crescentic formation is
more common in AAV than in SLE. Therefore, AAV might
have higher level of inflammation and lead to more apoptotic
or necrotic cells, and then more C4d might be produced
during the process of clearing apoptotic or necrotic cells.
In the current study, another interesting finding was that
in the remission stage of AAV, in contrast to plasma C5a and
Sc5b-9 levels that decreased to normal levels, plasma C3a
levels were still significantly higher than that in normal
controls. It seemed that the terminal part of the complement
cascade became quiescent in the remission stage, and C3
activation was not followed by C5 activation or membrane
attack complex formation. The reasons remain speculative,
but may also be associated with the clearance of apoptotic
bodies because C3b is an important opsonin. C3b fragments
are under strict control by a complex system of serum and
membrane proteins. CR1 is a receptor for the complement
fragments C3b and C4b and is expressed on many different
cell types. It allows phagocytic cells to ingest particles that
have activated complement and promotes the cleavage of C3b
and C4b by the serum enzyme C3b/C4b inactivator.20 Many
other complement regulators, such as CD55, CD46, and
factor H, could also inhibit complement amplification via
targeting on different components.21 All of the above may
contribute to the regulating mechanism preventing C3b from
activating C5 in the remission stage of AAV. However, the
exact mechanism still needs further investigation.
In the present study, no positive correlation between the
plasma levels and the renal deposits of complement com-
ponents was observed. As a systemic disease, the circulating
complement activation status might not necessarily correlate
with the local renal complement activation status.
In conclusion, the present study provided direct evidence
for that systemic activation of complement via the alternative
pathway occurred in human AAV. Circulating level of
fragment Bb might be a useful biomarker in monitoring
systemic disease activity and renal disease activity in AAV.
MATERIALS AND METHODS
Patients and blood samples
Sixty-six patients with active AAV, diagnosed at the Peking
University First Hospital from January 2007 to December 2010,
were enrolled in this study. All the patients had renal involvement
and received renal biopsy. Plasma samples of these patients
were collected on the day of renal biopsy and before commencing
the immunosuppressive treatment. Plasma samples of 54 patients
with AAV, who achieved complete remission, as described
previously,22 after immunosuppressive therapy, were also collected
at their regular ambulatory visits between January 2011 and
April 2012. There were 20 patients who had plasma samples both
in active stage and remission. All these 100 patients were positive
for perinuclear ANCA (P-ANCA) and MPO-ANCA at diagnosis.
All the patients met the Chapel Hill Consensus Conference
definition of AAV23 and had complete clinical and pathological
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data. Patients with secondary vasculitis or with coexistence of other
renal disease were excluded.
Plasma samples of 39 age- and gender-matched healthy blood
donors and 46 patients with renal biopsy-proven diffuse lupus
nephritis (class IV, according to the abbreviated version of the ISN/
RPS classification24) in active stage, diagnosed in the same period in
our center, were collected as normal control and disease control,
respectively. All the patients with lupus nephritis fulfilled the 1997
American College of Rheumatology revised criteria for SLE.25
The blood samples of patients and controls were drawn into
EDTA tubes and put on ice immediately. The blood samples were
centrifuged at 2000 g for 15 min at 4 1C within 30 min after
collection and the plasma was stored in aliquot at 80 1C until
use. When testing, after rapid thawing at 37 1C, the frozen specimens
were transferred immediately onto ice before use within 1 h.
Repeated freeze/thaw cycles were avoided. The research was in
compliance with the Declaration of Helsinki Principles and
approved by the ethics committee of our hospital. Written informed
consent was obtained from each participant.
Quantification of plasma complement components levels
Plasma concentrations of human complement components were
determined by enzyme-linked immunosorbent assay, including
complement fragments C5a (Quidel, San Diego, CA), C3a (Quidel),
Bb (Quidel), soluble C5b-9 (Sc5b-9, Quidel), properdin (Uscnk Life
Science, Wuhan, China), C4d (Quidel), C4 (Abcam, Cambridge,
UK), C2 (Uscnk Life Science), and factor B (Uscnk Life Science).
All the complement components were assayed according to the
manufacturer’s instructions.
Renal histology
Renal histology of patients with AAV was evaluated according to the
previous standardized protocol.26–28 The presence of glomerular
lesions, including fibrinoid necrosis, crescents, and glomerulo-
sclerosis, were calculated as the percentage of the total number of
glomeruli in a biopsy.
Detection of renal deposition of complement components by
immunohistochemistry
Renal specimens from 29 patients in active stage of AAV, who were
randomly selected from the 66 patients described above, were
included for the immunohistochemistry study.
C3d, one of the products derived from C3 activation, could bind
covalently via thiolester bond to its acceptor molecule at the activated
site.29 Therefore, we detected the C3 activation in renal specimen by
C3d staining. In the present study, staining of complement
components was performed by immunohistochemistry as previously
described.7 As our previous study already proved that staining of
C4d, the common component of the classic and lectin pathway, was
negative in the renal specimen of ANCA-associated glomerulone-
phritis,7 we stained Bb, C3d, and C5b-9 in renal specimens.
Staining of complement components was performed by im-
munohistochemistry as previously described.7 Immunohistochem-
ical staining for Bb, C3d, and C5b-9 was performed on 4-mm
deparaffinized sections of formaldehyde-fixed renal tissue using
mouse anti-human Bb monoclonal antibodies (Quidel), rabbit anti-
human C3d polyclonal antibodies (Dako A/S, Copenhagen, Den-
mark) and mouse anti-human C5b-9 monoclonal antibodies
(Abcam) as primary antibodies. Antibodies against Bb, C3d, and
C5b-9 were used in dilutions of 1:50, 1:500, and 1:50, respectively.
The sections for C3d staining were treated with 0.4% pepsin
(Zhongshan Golden Bridge Biotechnology, Beijing, China) 45 min
for antigen retrieval. The sections for staining Bb and C5b-9 were
treated with 0.5 mg/ml proteinase K for antigen retrieval.
The sections were examined by light microscopy. The renal
staining of Bb, C3d, and C5b-9 in glomeruli was evaluated by
the Image Pro Plus analysis software 6.05 (Media Cybernetics, Silver
Spring, MD). The positive signals were quantified as the mean
optical density (integrated option density/area).
Statistical analysis
Differences of quantitative parameters between groups were assessed
using the t-test (for normally distributed data) or nonparametric
test (for non-normally distributed data). The relationships between
two continuous variables were analyzed using Spearman’s rank
correlation. The difference was considered significant if a P-value
was o0.05. Analysis was performed with SPSS statistical software
package (version 13.0, Chicago, IL).
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